Abstract
The protective effects of intranasal administration of amphotericin B (AmB), human SP-A, SP-D and a 60-kDa fragment of SP-D (rSP-D) were examined in a murine model of invasive pulmonary aspergillosis (IPA). The untreated group of IPA mice showed no survival at 7 days postinfection. Treatment with AmB, SP-D, and rSP-D increased the survival rate to 80, 60, and 80%, respectively, suggesting that SP-D (and rSP-D) can protect immunosuppressed mice from an otherwise fatal challenge with Aspergillus fumigatus conidia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / therapeutic use
-
Animals
-
Aspergillosis / drug therapy*
-
Aspergillosis / immunology
-
Glycoproteins / therapeutic use*
-
Lung Diseases, Fungal / drug therapy*
-
Lung Diseases, Fungal / immunology
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Peptide Fragments / therapeutic use
-
Proteolipids / therapeutic use
-
Pulmonary Surfactant-Associated Protein A
-
Pulmonary Surfactant-Associated Protein D
-
Pulmonary Surfactant-Associated Proteins
-
Pulmonary Surfactants / therapeutic use*
Substances
-
Glycoproteins
-
Peptide Fragments
-
Proteolipids
-
Pulmonary Surfactant-Associated Protein A
-
Pulmonary Surfactant-Associated Protein D
-
Pulmonary Surfactant-Associated Proteins
-
Pulmonary Surfactants
-
Amphotericin B